What's breaking now, across thousands of outlets.
Plus, news about Vor Bio, RemeGen, Merck KGaA, Aidea, Astellas and Immuneering. BioNTech acquires PRV for $205 million: The German biotech scooped up the FDA voucher from Scholar Rock, with plans ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
With a standardized cell naming system and infrastructure for data collection and analysis, the basal ganglia project sets the stage for a whole-brain primate atlas.
Researchers at Arizona State University, U.S., have found that a high-fat diet leaves lasting changes in intestinal stem cells, potentially increasing the risk of tumor development.
One blood marker could show if a patient has serous tubal intraepithelial carcinoma, an early sign of advanced ovarian cancer.
The World Bank has urged Nigerian state governments to sustain gains recorded in child survival, malaria prevention, and immunisation under the IMPACT proj Read More…
EnGene’s latest data on its bladder cancer therapy looked better than an earlier cut in May, which had gutted the biotech’s stock after it reported underwhelming durability results.
